Vir Biotechnology is a clinical-stage company with extraordinary analyst upside of 150% and an asymmetry ratio of 10.95x, but it has missed earnings in three of four recent quarters, burns cash at negative 328% of revenue, and scores below the minimum quality threshold at 1.9 out of 10, making it a speculative bet on late-stage clinical pipeline success.
Thesis pillars
- Analyst Upside Clinical Option Value→Stable
- Earnings Miss Streak Execution Risk→Stable
- High Short Interest Momentum Recovery→Stable
- +1 more pillar — see the Why tab for full reasoning
Vir Biotechnology, Inc. (VIR) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.54: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 54.00; Below-average business quality.
Vir Biotechnology is a clinical-stage biopharmaceutical company developing antibody and RNA-based therapies for infectious diseases and cancer, powered by its proprietary dAIsY AI antibody-discovery platform and an exclusive PRO-XTEN masking platform in-licensed from Sanofi. Its... Read more
Sell if holding. Engine safety override at $9.54: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 54.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Score 4.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Vir Biotechnology, Inc.
About Vir Biotechnology, Inc.
Vir Biotechnology's most advanced program, the tobevibart-elebsiran antibody-siRNA combination for chronic hepatitis delta, entered registrational Phase 3 trials (ECLIPSE 1, 2, and 3) in March 2025, with topline results expected in the fourth quarter of 2026 and first quarter of 2027. The company also advances three Phase 1 T-cell engager oncology candidates and an HIV cure program. Vir held $781.6 million in cash and investments at December 31, 2025, following a $438.0 million net loss for the year and a $1.2 billion accumulated deficit.
Vir has no approved products generating meaningful revenue today; its combination of tobevibart and elebsiran for chronic hepatitis delta incorporates Xencor's Xtend Fc-extension technology and Vir's proprietary antibody engineering, while three oncology T-cell engager candidates (VIR-5500, VIR-5818, VIR-5525) rely on the exclusive PRO-XTEN masking platform in-licensed from Sanofi's Amunix Pharmaceuticals unit for worldwide oncology and infectious-disease rights. The company has out-licensed regional commercial rights for the CHD combination to Norgine (Europe, Australia, New Zealand) and granted Brii Biosciences an option for Greater China rights, while its HIV broadly neutralizing antibody program builds on antibodies in-licensed from Togontech GmbH with support from the Gates Foundation. Vir relies on third parties to manufacture clinical and, if approved, commercial drug supply, and to conduct and monitor its preclinical and clinical studies.
Show full overview
Vir's oncology ambitions run through a single external license: all three of its clinical-stage T-cell engagers depend on the PRO-XTEN masking technology that Vir exclusively in-licensed from Sanofi's Amunix unit, meaning a breach, dispute, or termination of that agreement could simultaneously impair VIR-5500, VIR-5818, and VIR-5525 rather than just one program. The 10-K's risk factors explicitly warn that breaching license agreements underlying acquired intellectual property could cost the company the ability to continue developing and commercializing the related candidates. That concentrates Vir's oncology pipeline risk in a counterparty relationship rather than in Vir's own proprietary science, a different risk profile than its infectious-disease programs, which rely more heavily on internally engineered antibodies.
See also: Healthcare · Biotechnology
From Vir Biotechnology, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Vir Biotechnology, Inc.
Latest news
- NEWS Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27 — benzinga Jun 11, 2026 positive
- NEWS Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21 — benzinga Jun 3, 2026 positive
- NEWS Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chroni — benzinga May 18, 2026 positive
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- NEWS Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY. — benzinga May 6, 2026 negative
Generated 2026-07-07T13:21:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyPRO-XTEN platform license (Sanofi/Amunix)10-K Item 1: 'the exclusive PRO-XTEN® (a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company) masking platform, which we in-licensed from Sanofi for worldwide rights in oncology and infectious diseases.'
Material Events(8-K, last 90d)
- 2026-06-10Item 5.02LOWBoard of Directors expanded from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director and Chair of the Audit Committee, effective June 9, 2026.SEC filing →
- 2026-05-28Item 5.02MEDIUMDirector and Audit Committee Chair Saira Ramasastry stepped down effective May 26, 2026 due to a business conflict, not a disagreement with the company; Robert More was appointed the new Audit Committee Chair and the board was reduced from eight to seven members.SEC filing →
- 2026-05-28Item 5.07LOWThe company held its 2026 Annual Meeting of Stockholders on May 26, 2026; the source filing text describing voting results was truncated.SEC filing →
- 2026-04-10Item 5.02MEDIUMEVP and Chief Medical Officer Mark Eisner informed the company on April 7, 2026 that he will step down effective April 24, 2026; a search for his successor was initiated, with no successor named in this filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 5.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.54: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 54.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Prior stop was $9.32. Score 4.2/10, moderate confidence.
Take-profit target: $18.75 (+87.1% upside). Prior stop was $9.32. Stop-loss: $9.32.
Concentration risk — Counterparty: PRO-XTEN platform license (Sanofi/Amunix); Quality below floor (1.9 < 4.0); Value-trap signals (2/5): High leverage (D/E 8.5), Material insider selling (6 sells, 0.08% of cap).
Vir Biotechnology, Inc. trades at a P/E of N/A (forward -4.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover VIR with a consensus score of 4.2/5. Average price target: $22.
What does Vir Biotechnology, Inc. do?Vir Biotechnology is a clinical-stage biopharmaceutical company developing antibody and RNA-based therapies for...
Vir Biotechnology is a clinical-stage biopharmaceutical company developing antibody and RNA-based therapies for infectious diseases and cancer, powered by its proprietary dAIsY AI antibody-discovery platform and an exclusive PRO-XTEN masking platform in-licensed from Sanofi. Its lead program, the tobevibart-elebsiran combination for chronic hepatitis delta, is in registrational Phase 3 trials, alongside three Phase 1 T-cell engager oncology candidates and an HIV cure program.